Technology
Health
Biotechnology

Synlogic

$8.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Synlogic and other stocks, options, ETFs, and crypto commission-free!

About

Synlogic, Inc. Common Stock, also called Synlogic, is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. Read More It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Employees
74
Headquarters
Cambridge, Massachusetts
Founded
2017
Market Cap
208.19M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
111.61K
High Today
$8.34
Low Today
$7.95
Open Price
$8.32
Volume
18.01K
52 Week High
$14.59
52 Week Low
$5.75

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2015 IPO

News

Seeking AlphaMay 22

Synlogic teams up with Roche in potential combo therapy for solid tumors

Synlogic (NASDAQ:SYBX) will collaborate with Roche (OTCQX:RHHBY) on clinical studies evaluating the combination of SYNB1891, a STING agonist, and Tecentriq (atezolizumab) in patients with advanced solid tumors.

35
Seeking AlphaMay 12

Synlogic, Inc. CEO Aoife Brennan on Q1 2019 Results - Earnings Call Transcript

Synlogic, Inc. (NASDAQ:SYBX) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Elizabeth Wolffe - Head, IR and Corporate Communications Aoife Brennan - President, CEO, and CMO Scott Plevy - CSO Todd Shegog - CFO Conference Call Participants Mark Breidenbach - Oppenheimer & Co Inc. Joseph Schwartz - SVB Leerink Samantha Semenkow - Citigroup Ted Tenthoff - Piper Jaffray & Co. Edward Marks - H.C. Wainwright & Co. Chris Howerton - Jefferies Julian Harrison - BTIG ...

23
Yahoo FinanceMay 9

Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- – Company will host a conference call and webcast at 5:00 pm ET today – Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the first quarter ended March 31, 2019. “We made significant progress on our 2019 goals in the first quarter of the year providing a strong foundation for the continued development of our Synthetic Biotic™ platform and...

28

Earnings

-$1.66
-$1.25
-$0.84
-$0.43
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.